ERBB2 and breast carcinoma: Notably, patients with HR+/HER2- and HER2+ breast cancer subtypes were more likely to remain on their systemic therapy following MDRT, although whether this is due to inherit differences in prognosis or the effect of MDRT remains uncertain due to the lack of a control group.